Investigating how cold viruses affect bronchiectasis exacerbations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine whether viral infections, specifically rhinovirus, lead to exacerbations in patients with bronchiectasis. Participants will be divided into two groups: those with bronchiectasis and healthy individuals. After screening and baseline investigations, participants will be exposed to a rhinovirus and monitored over six weeks through various procedures, including blood tests and bronchoscopy, to assess immune responses and exacerbation triggers. The research seeks to enhance understanding of how viral infections impact bronchiectasis and may inform future treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* For healthy volunteers:

  1\) Age 18 to 65 years.
* For bronchiectasis study subjects:

  1. Confirmed diagnosis of bronchiectasis aged 18-65 years with bronchiectasis severity index score of 0-8 .
  2. For Pseudomonas colonised individuals, isolation of Pseudomonas aeruginosa in two or more cultures, at least 3 months apart in a 2-year period.

Exclusion Criteria:

* For healthy volunteers and bronchiectasis study subjects:

  1. Any medical co-morbidity impacting the study in the opinion of the medical team
  2. Current smoking history within last 12 months or ex smoking history \>5 pack years
  3. Pre-existing serum neutralising antibodies to RV-A16 (strain to be used for challenge)
  4. Close contact with infants or elderly individuals either at home or workplace
  5. Pregnancy or breastfeeding
* For bronchiectasis study subjects:

  1\) Individuals with bronchiectasis secondary to cystic fibrosis, primary immunodeficiency, primary ciliary dyskinesia and allergic bronchopulmonary aspergillosis 2) Individuals with other significant chronic lung disease diagnoses (eg. interstitial lung disease) which would impact the study in the opinion of the medical team 4) FEV1 \< 50% predicted 8) Recent antibiotics for exacerbations within the preceding 6 weeks and prophylactic antibiotics (azithromycin or nebulised antibiotics) within preceding 4 weeks 9) Corticosteroid use (inhaled, nasal or systemic) within preceding 4 weeks.

Where it's running

• St Mary's Hospital - Imperial Clinical Respiratory Research Unit (ICRRU)
  London, United Kingdom Recruiting

Study contacts

• Principal investigator: Anand Shah, PhD — Imperial College London
• Study coordinator: Charlotte E Carter, MBChB
• Email: cecarter@ic.ac.uk
• Phone: +447814752750

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Azithromycin added to usual care to see if it lowers bronchiectasis flare-ups

  This trial tests whether taking azithromycin daily for a year reduces bronchiectasis-related flare-ups in adults with non-cystic fibrosis bronchiectasis.

  Recruiting Phase 4 Assiut University · Asyut · NCT07608328

• How viral infections affect people with chronic lung disease

  This study will test if respiratory viruses trigger flare-ups and change immune responses in adults with COPD or bronchiectasis.

  Recruiting Imperial College London · London · NCT06625944

• Bronchoscopic Amikacin for Acute Exacerbations in Bronchiectasis

  This study tests whether delivering amikacin directly into the lungs during bronchoscopy helps adults with acute bronchiectasis flare-ups.

  Recruiting First Affiliated Hospital of Ningbo University · Ningbo, Zhejiang · NCT07813299

• CTX-187 first-in-human test in healthy people and people with chronic bronchiectasis and Pseudomonas infection

  This study tests CTX-187 to see if it is safe and tolerable when given as IV infusions to healthy adults and adults with chronic bronchiectasis and Pseudomonas aeruginosa infection.

  Recruiting Phase 1 Centauri Therapeutics Limited · Groningen · NCT07708116

• Tele-Pulmonary Rehabilitation for Chronic Lung Diseases

  This study tests whether a remote tele-rehabilitation program helps people with chronic lung diseases start and stick with pulmonary rehab better than usual center-based care.

  Recruiting at 2 sites Tel-Aviv Sourasky Medical Center · Ashkelon and 1 other locations · NCT07666841

• Biomarkers linked to congenital CMV using newborn blood spots

  Researchers will test protein and RNA markers in dried blood spots from newborns to see if they can identify congenital CMV sequelae early.

  Recruiting at 2 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT07635368

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.